Selina M. Luger, M.D., FRCPC
Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-157
34th and Civic Center Blvd
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-157
34th and Civic Center Blvd
Philadelphia, PA 19104
Office: 215-614-1847
Fax: 215-615-5888
Fax: 215-615-5888
Education:
A.B. (Biochemistry)
Harvard University, 1982.
M.D.CM (Medicine)
McGill University, 1987.
Permanent linkA.B. (Biochemistry)
Harvard University, 1982.
M.D.CM (Medicine)
McGill University, 1987.
Description of Research Expertise
Leukemia, myelodysplastic syndrome, myeloproliferative disordersMDS, AML, CML, ALL
Description of Clinical Expertise
hematologic malignancies, leukemia, AML, ALL, CML, myelodysplastic syndrome, MDS, myeloproliferative disorders, stem cell transplantation, bone marrow transplantSelected Publications
Chow RD, Velu P, Deihimi S, Belman JP, Youn A, Shah N, Luger SM, Carroll MP, Morrissette JJ, Bowman RL.: Persistent post-remission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia. Blood Adv Feb 2025.Jillella AP, Lee SJ, Altman JK, Luger SM, Tallman MS, Foran JM, Bradshaw D, Law LY, Bryan LJ, Abou Zahr A, Begna KH, Perl AE, Vadakara JJL, Qamar R, Bergan RC, Fisch MJ, Carlos RC, Wagner LI, Kota VK, Litzow MR.: Academic Community Partnership in Acute Promyelocytic Leukemia and Early MortalityThe ECOG-ACRIN EA9131 Trial. JAMA Oncol. Feb 2025.
Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C.: Evolving racial/ethnic disparities in AML survival in the novel therapy era. Blood Adv 9: 533-544, Feb 2025.
Rowe, M., Babushok, D., Carroll, M., Carulli, A., Frey, N., Gill, S., Hexner, E., Hirsh, R., Hossain, N., Lai, C., Loren, A., Luger, S., Maillard, I., McCurdy, S., Matthews, A., Martin, M.E., Paralkar, V.R., Perl, A., Porter, D., Pratz, K., Stadtmauer, E. and Bruno, X.J. : Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. Eur J Haematol 2025.
Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ.: Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. Eur J Haematol Dec 2024.
Niedersuess-Beke D, Mayrhofer K, Krauter J, Schnabel S, Gampenrieder SP, Miechowiecki J, Kiesl D, Luger F, Pfuner J, Wiesinger C, Vallet S, Andalibi H, Vais D, Banner A, Stoiber F, Spielgelberg J, Barth D, Bauernhofer T, Aufderklamm S, Weibrecht S, Mühlmann J, Mayer M, Hilbe W, Boulmé F, Klinglmair G, Heintel D, Shariat SF, Pichler M, Pichler R.: Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study. Clin Genitourin Cancer Nov 2024.
Bijal Shah MD, Ryan J. Mattison MD, Ramzi Abboud MD, Peter Abdelmessieh DO, MSc, Ibrahim Aldoss MD, Patrick W. Burke MD, Daniel J. DeAngelo MD, PhD, Shira Dinner MD, Amir T. Fathi MD, Jordan Gauthier MD, MSc, Michael Haddadin MD, Nitin Jain MD, Brian Jonas MD, PhD, Suzanne Kirby MD, Michaela Liedtke MD, Mark Litzow MD, Aaron Logan MD, PhD, Meixiao Long MD, PhD, Selina Luger MD, James K. Mangan MD, PhD, Stephanie Massaro MD, MPH, William May MD, Olalekan Oluwole MD, Jae Park MD, Amanda Przespolewski DO, Sravanti Rangaraju MD, Caner Saygin MD, Marc Schwartz MD, Paul Shami MD, Benjamin Tomlinson MD, Jonathan Webster MD, Ajibola Awotiwon MBBS, MSc, and Katie Stehman MMS, PA-C: Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 22(8), Oct 2024.
Kimura S, Park CS, Montefiori LE, Iacobucci I, Pölönen P, Gao Q, Arnold ED, Attarbaschi A, Brown A, Buldini B, Caldwell KJ, Chang Y, Chen C, Cheng C, Cheng Z, Choi J, Conter V, Crews KR, de Groot-Kruseman HA, Deguchi T, Eguchi M, Muhle HE, Elitzur S, Escherich G, Freeman BB 3rd, Gu Z, Han K, Horibe K, Imamura T, Jeha S, Kato M, Chiew KH, Khan T, Kicinski M, Köhrer S, Kornblau SM, Kotecha RS, Li CK, Liu YC, Locatelli F, Luger SM, Paietta EM, Manabe A, Marquart HV, Masetti R, Maybury M, Mazilier P, Meijerink JPP, Mitchell S, Miyamura T, Moore AS, Oshima K, Pawinska-Wasikowska K, Pieters R, Prater MS, Pruett-Miller SM, Pui CH, Qu C, Reiterova M, Reyes N, Roberts KG, Rowe JM, Sato A, Schmiegelow K, Schrappe M, Shen S, Skoczeń S, Spinelli O, Stary J, Svaton M, Takagi M, Takita J, Tang Y, Teachey DT, Thomas PG, Tomizawa D, Trka J, Varotto E, Vincent TL, Yang JJ, Yeoh AEJ, Zhou Y, Zimmermann M, Inaba H, Mullighan CG.: Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk. Cancer Discov Oct 2024.
Badar T, Luger SM, Litzow MR: Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia. Blood Sep 2024.
Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, Farooki SN, Frost BF, Loken MR, Gaymon AL, Frazee D, Rogal W, Frey N, Hexner EO, Luger SM, Loren AW, Martin ME, McCurdy SR, Perl AE, Stadtmauer EA, Brogdon JL, Fraietta JA, Hwang WT, Siegel DL, Plesa G, Aplenc R, Porter DL, June CH, Gill SI.: Cytokine-mediated CAR T therapy resistance in AML. Nat Med Sep 2024.